Approved Use: Aimovig® is a prescription medicine used for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

Who should not use Aimovig®?

Do not use Aimovig® if you are allergic to erenumab-aooe or any ingredients in Aimovig®.

Before starting Aimovig®, tell your healthcare provider (HCP) about all your medical conditions, including if you are allergic to rubber or latex, pregnant or plan to become pregnant, breastfeeding or plan to breastfeed.

Tell your HCP about all the medicines you take, including any prescription and over-the-counter medicines, vitamins, or herbal supplements.

What are possible side effects of Aimovig®?

Aimovig® may cause serious side effects, including:

  • Allergic reactions. Allergic reactions, including rash or swelling can happen after receiving Aimovig®. This can happen within hours to days after using Aimovig®. Call your HCP or get emergency medical help right away if you have any of the following symptoms of an allergic reaction: swelling of the face, mouth, tongue or throat, or trouble breathing.

  • Constipation with serious complications. Severe constipation can happen after receiving Aimovig®. In some cases people have been hospitalized or needed surgery. Contact your HCP if you have severe constipation.

The most common side effects of Aimovig® are pain, redness, or swelling at the injection site and constipation.

These are not all of the possible side effects of Aimovig®. Call your HCP for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Click here for the full Prescribing Information and Patient Product Information.

APPROVED USE

Aimovig® is a prescription medicine used for the preventive treatment of migraine in adults.

the team behind Aimovig is on a mission beyond medicine

A mission to challenge public misconceptions, start new conversations, and make the world a more migraine-friendly place. Join us and help spread the knowledge and acceptance.

 
 

the truth
about migraine

18% of women
and
6% of men

Migraine is more than just a headache—it’s a complex neurological disease that affects 18% of women and 6% of men in the U.S.

A single migraine episode can last up to 72 hours. Nearly 50% of people with chronic migraine said they couldn’t work while experiencing migraine.

Migraine is one of the leading causes of years lived with disability, according to the Global Burden of Disease Study.

Fighting migraine can be a way of life—it is something that people may have to manage in their everyday lives, and it can keep them from doing the things they love most.

Migraine impacts people in different ways. There are a variety of symptoms that can occur—ranging from pulsating headaches to nausea, to sensitivity to sound. Some people may experience only a few migraine days per month, while people with chronic migraine may be affected on many more days.

helping all of us understand migraine better

The way migraine can be treated has changed, but the way people with migraine are treated still has a long way to go. So Novartis, part of the team behind Aimovig, financed the largest survey to-date of people with severe migraine, My Migraine Voice. The global, cross-sectional study aimed at understanding the burden and impact of migraine directly from patients.

migraine in the workplace

Amgen, part of the team behind Aimovig, is leading the charge to create a more supportive work environment for people with migraine. They've enacted real change in their workplace through migraine well-being initiatives focused on migraine awareness, education and management and are working with other Fortune 500 companies to help them do the same.

 

guides with tips
to help you talk to your boss

 

The list of resources and links above is not exhaustive. These resources and links were created by independent third parties, and Amgen and Novartis do not endorse any of these resources or the entities sponsoring these links.

what you can do

 

The more vocal and visible we all are, the more people will recognize that this disease affects millions of us. So, get involved, look for support groups in your area, join a fun run—anything to help spread the acceptance.

Know-migraine-mission
contact us here 1-833-AIMOVIG (1-833-246-6844)
8 AM-8 PM ET, Mon-Fri

IMPORTANT SAFETY INFORMATION

Who should not use Aimovig®?

Do not use Aimovig® if you are allergic to erenumab-aooe or any ingredients in Aimovig®.

Before starting Aimovig®, tell your healthcare provider (HCP) about all your medical conditions, including if you are allergic to rubber or latex, pregnant or plan to become pregnant, breastfeeding or plan to breastfeed.

Tell your HCP about all the medicines you take, including any prescription and over-the-counter medicines, vitamins, or herbal supplements.

What are possible side effects of Aimovig®?

Aimovig® may cause serious side effects, including:

  • Allergic reactions. Allergic reactions, including rash or swelling can happen after receiving Aimovig®. This can happen within hours to days after using Aimovig®. Call your HCP or get emergency medical help right away if you have any of the following symptoms of an allergic reaction: swelling of the face, mouth, tongue or throat, or trouble breathing.

  • Constipation with serious complications. Severe constipation can happen after receiving Aimovig®. In some cases people have been hospitalized or needed surgery. Contact your HCP if you have severe constipation.

The most common side effects of Aimovig® are pain, redness, or swelling at the injection site and constipation.

These are not all of the possible side effects of Aimovig®. Call your HCP for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Click here for the full Prescribing Information and Patient Product Information.

APPROVED USE

Aimovig® is a prescription medicine used for the preventive treatment of migraine in adults.